12:00 AM
Apr 27, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xarelto rivaroxaban regulatory update

The U.K.'s NICE issued final guidance recommending use of Xarelto rivaroxaban from Bayer to prevent venous thromboembolism (VTE) in adults having elective total hip or knee replacement surgery....

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >